Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Sufentanil SSM

Small molecule · developed by Talphera

Phase 1 Most advanced trial (none active)
TLPH Developer
1 Registered trials

What is Sufentanil SSM?

Sufentanil SSM is the drug name only; the source texts provided say nothing further about its pharmacology, targets or uses.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Developer
Talphera, Inc (TLPH)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02082236 Phase 1 Healthy Completed TLPH

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy

More from Talphera

Follow TLPH, the company behind Sufentanil SSM

See TLPH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TLPH catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.